Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer
Clinical trial NCT02305186 · UNKNOWN
Trial details
- NCT number
- NCT02305186
- Sponsor
- Craig L Slingluff, Jr
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-01
- Primary completion
- 2022-12-01
- Enrollment
- 68
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.